Genomic risk distribution, adjuvant chemotherapy trends, and survival outcomes in women with pT1, grade 1-2, ER/PR-positive, LVI-negative breast cancer
{{output}}
Background: Oncotype DX Recurrence Score (RS) guides adjuvant chemotherapy decisions in early-stage hormone receptor-positive (HR+), HER2-negative breast cancer (BC). However, the survival benefit of adjuvant chemotherapy in pati... ...
